BiotechTube

Mavacamten

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Symptomatic Obstructive Hypertrophic Cardiomyopathy

Conditions

Symptomatic Obstructive Hypertrophic Cardiomyopathy

Trial Timeline

Sep 4, 2025 → Dec 13, 2027

NCT ID
NCT07004972

About Mavacamten

Mavacamten is a approved stage product being developed by Bristol Myers Squibb for Symptomatic Obstructive Hypertrophic Cardiomyopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07004972. Target conditions include Symptomatic Obstructive Hypertrophic Cardiomyopathy.

What happened to similar drugs?

2 of 16 similar drugs in Symptomatic Obstructive Hypertrophic Cardiomyopathy were approved

Approved (2) Terminated (4) Active (10)
❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
🔄ISV-305Sun PharmaceuticalPhase 3
🔄rabeprazole sodium + PlaceboEisaiPhase 3
🔄Esomeprazole + Matching placeboAstraZenecaPhase 3
🔄Pasireotide + OctreotideNovartisPhase 3
✅valsartanNovartisApproved
🔄Apixaban + Standard of carePfizerPhase 3

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (19)

NCT IDPhaseStatus
NCT07361289Pre-clinicalRecruiting
NCT07004972ApprovedRecruiting
NCT07383025Pre-clinicalRecruiting
NCT06146660Pre-clinicalRecruiting
NCT06338202Pre-clinicalCompleted
NCT06551129Pre-clinicalRecruiting
NCT06549608Pre-clinicalActive
NCT06112743ApprovedActive
NCT07107373Pre-clinicalActive
NCT05939700Pre-clinicalRecruiting
NCT06023186Pre-clinicalRecruiting
NCT07168655Pre-clinicalCompleted
NCT05719805Phase 1Completed
NCT05582395Phase 3Completed
NCT05414175Phase 3Completed
NCT05362045Phase 1Completed
NCT04766892Phase 2Completed
NCT03723655Phase 2/3Completed
NCT03496168Phase 2Completed

Competing Products

20 competing products in Symptomatic Obstructive Hypertrophic Cardiomyopathy

See all competitors
ProductCompanyStageHype Score
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
32
ISV-305Sun PharmaceuticalPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40
Verinurad + Febuxostat + DapagliflozinAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32
Esomeprazole + Matching placeboAstraZenecaPhase 3
40
DFV890 + PlaceboNovartisPhase 2
35
Omalizumab + Omalizumab + PlaceboNovartisPhase 2
35
Pasireotide + OctreotideNovartisPhase 3
40
TegaserodNovartisPhase 2
35
valsartanNovartisApproved
43
Atorvastatin - Cholestyramine - SitosterolPfizerPre-clinical
26
Epoetin biosimilarPfizerPre-clinical
26
Apixaban + Standard of carePfizerPhase 3
40
Azithromycin plus chloroquinePfizerPhase 3
32
Aficamten + PlaceboSanofiPhase 3
44
Vandetanib 300 mgSanofiPre-clinical
26
REGN7508 + Acetylsalicylic Acid (ASA) + PlaceboRegeneron PharmaceuticalsPhase 3
47
Rivaroxaban + PlaceboBayerPhase 3
37
Droxidopa capsules + Placebo capsulesLundbeckApproved
40